1. Korosh K, Ur M, Wilson S R. Hilar biliary obstruction: preliminary results with Levovist-enhanced sonography. Ajr American Journal of Roentgenology, 2003, 180(3):687-693.
2. Klatskin G. Adenocarcinoma of the hepatic duct at its bifurcation within the porta hepatis: An unusual tumor with distinctive clinical and pathological features. American Journal of Medicine, 1965, 38(2):241-56.
3. Lang H , Kaiser G M, Zöpf T, et al. Surgical therapy of hilar cholangiocarcinoma. Der Chirurg, 2006, 77(4):325-34.
4. Thuluvath P J, Rai R, Venbrux A C, et al. Cholangiocarcinoma: a review. Gastroenterologist, 1997, 5(4):306-15.
5. Nakayama A , Imamura H , Shimada R , et al. Proximal bile duct stricture disguised as malignant neoplasm. Surgery, 1999, 125(5):514-21.
6. Singh SS, Sharma R, Pal S, et al. Differentiation between benign and malignant hilar obstructions using laboratory and radiological investigations: A prospective study. HPB(Oxford) 2007; 9: 373-382.
7. Knoefel W T, Prenzel K L, Peiper M, et al. Klatskin tumors and Klatskin mimicking lesions of the biliary tree. European Journal of Surgical Oncology, 2003, 29(8):658-661.
8. Binkley CE, Eckhauser FE, Colletti LM. Unusual causes of benign biliary strictures with cholangiographic features of cholangiocarcinoma. Gastrointest Surg,2002; 6: 676-681.
9. Saxena A, Chua TC, Chu FC, Morris DL. Improved outcomes after aggressive surgical resection of hilar cholangiocarcinoma: a critical analysis of recurrence and survival. Am J Surg. 2011; 202:310–20.
10. DeOliveira ML, Cunningham SC, Cameron JL, Kamangar F, Winter JM, Lillemoe KD, Choti MA, Yeo CJ, Schulick RD. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg. 2007; 245:755–62.
11. Kow AW, Wook CD, Song SC, Kim WS, Kim MJ, Park HJ, Heo JS, Choi SH. Role of caudate lobectomy in type III A and III B hilar cholangiocarcinoma: a 15-year experience in a tertiary institution. World J Surg. 2012; 36:1112–21.
12. Jaap Jacob Kloek, Otto Marinus van Delden, Deha Erdogan.Differentiation of malignant and benign proximal bile duct strictures: The diagnostic dilemma.World J Gastroenterol.2008:28; 14(32): 5032-5038.
13. Paritpokee N , Tangkijvanich P , Teerasaksilp S , et al. Fast liver alkaline phosphatase isoenzyme in diagnosis of malignant biliary obstruction. Journal of the Medical Association of Thailand, 1999, 82(12):1241-6.
14. Saluja SS, Sharma R, Pal S, Sahni P, Chattopadhyay TK. Differentiation between benign and malignant hilar obstructions using laboratory and radiological investigations: a prospective study. HPB (Oxford), 2007;9:373–82.
15. Larisa Vasilieva,Stefanos I. Papadhimitriou,Alexandra Alexopoulou.Clinical presentation, diagnosis, and survival in cholangiocarcinoma: A prospective study.Arab Journal of Gastroenterology,2016:17;181–184.
16. Juntermanns B, Radunz S, Heuer M, et al. Tumor markers as a diagnostic key for hilar cholangiocarcinoma. European Journal of Medical Research, 2010, 15(8):357-61.
17. Siqueira E, Schoen RE, Silverman W, Martin J, Rabinovitz M, Weissfeld JL, Abu-Elmaagd K, Madariaga JR, Slivka A. Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. Gastrointest Endosc 2002; 56: 40-47
18. Khan SA, Davidson BR, Goldin R, Pereira SP. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut.2002; 51 Suppl 6: VI1-VI9.
19. Hamano H, Kawa S, Horiuchi A, Unno H. High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med 2001; 344: 732-738.
20. Ghazale A, Chari ST, Zhang L, Smyrk TC. Immunoglobulin G4- associated cholangitis: clinical profile and response to therapy. Gastroenterology 2008; 134: 706-715.
21. Bamrungphon W, Prempracha N, Bunchu N, et al. A new mucin antibody/enzyme-linked lectin-sandwich assay of serum MUC5AC mucin for the diagnosis of cholangiocarcinoma. Cancer letters, 2007,247(2):301-308.
22. Zhimin G,Noor H,Jian-Bo Z,et al.. Advances in diagnosis and treatment of hilar cholangiocarcinoma--a review. Med Sci Monit,2013,19: 648-656
23. Valls C,Ruiz S,Martinez L,et al. Radiological diagnosis and staging of hilar cholangiocarcinoma. World J Gastrointest Oncol,2013,5( 7) : 115-126.
24. Madhusudhan KS,Gamanagatti S,Gupta AK. Imaging and interventions in hilar cholangiocarcinoma: A revie. World J Radiol,2015,7( 2) : 28-44.
25. Hennedige TP,Neo WT,Venkatesh SK. Imaging of malignancies of the biliary tract-an update. Cancer Imaging,2014,14( 1) : 14.
26. Soares KC,Kamel I,Cosgrove DP,et al. Hilar cholangiocarcinoma: diagnosis,treatment options,and management. Hepatobiliary Surg Nutr,2014,3( 1) : 18-34.
27. Razumilava N,Gores GJ. Cholangiocarcinoma. Lancet,2014,383( 9935) : 2168-2179.
28. Rizvi S,Gores GJ. Pathogenesis,diagnosis and management of cholangiocarcinoma. Gastroenterology,2013,145( 6) : 1215-1229.
29. Sugita R. Magnetic resonance evaluations of biliary malignancy and condition at high-risk for biliary malignancy: Current status. World J Hepatol,2013,5( 12) : 654-665
30. Ho M,Kraiklang R,Pairojkul C,et al. A novel predictive equation for potential diagnosis of cholangiocarcinom. PLoSOne,2014, http: / /journals. plos. org / plosone /article? id = 10. 1371 /journal.pone.0089337.
31. Tamada K,Ushio J,Sugano K. Endoscopic diagnosis of extrahepatic bile duct carcinoma: Advances and current limitations.World J Clin Oncol,2011,2( 5) : 203-216.
32. Hidalgo E, Asthana S, Nishio H, Wyatt J, Toogood GJ,Prasad KR, Lodge JP. Surgery for hilar cholangiocarcinoma:the Leeds experience. Eur J Surg Oncol. 2008;34:787–94.
33. Ercolani G, Zanello M, Grazi GL, Cescon M, Ravaioli M, Del Gaudio M, Vetrone G, Cucchetti A, Brandi G,Ramacciato G, Pinna AD. Changes in the surgical approach to hilar cholangiocarcinoma during an 18-year period in a Western single center. J Hepatobiliary Pancreat Sci. 2010;17:329–37
34. Li H, Qin Y, Cui Y, Chen H, Hao X, Li Q. Analysis of the surgical outcome and prognostic factors for hilar cholangiocarcinoma: a Chinese experience. Dig Surg. 2011;28:226–31.
35. Dumitrascu T, Chirita D, Ionescu M, Popescu I. Resection for hilar cholangiocarcinoma: analysis of prognostic factors and the impact of systemic inflammation on long-term outcome. J Gastrointest Surg. 2013; 17:913–24
36. Croome KP, Rosen CB, Heimbach JK, Nagorney DM. Is Liver Transplantation Appropriate for Patients with Potentially Resectable De Novo Hilar Cholangiocarcinoma? J Am Coll Surg. 2015; 221:130–9.